Amarin reported $23.17M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amarin USD 23.17M 961K Dec/2025
AstraZeneca USD 12.86B 251M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026